Recurrent Pituitary Adenomas

Target Pituitary

Pituitary Adenomas

In reviewing 1300 patients with pituitary tumor referred to this center, recurrent pituitary adenomas comprise a significant fraction of patients.

Recurrent pituitary adenomas can result in the re-emergence of visual problems, as well as loss of pituitary function. In the case of hyperfunctioning tumors (such as prolactinomas, acromegaly and Cushing's disease), recurrent tumors may result in the recurrence of symptoms of hormone oversecretion.

Neuroendocrine Center Bulletin Archives

Management of Recurrent Pituitary Adenomas

Pituitary Home

Nicholas T. Zervas, M.D.
by Nicholas T. Zervas, M.D.


Recurrent pituitary adenomas require very careful study to determine the proper course of therapy. However, recurrent pituitary tumors can almost certainly be well treated. The treatment for recurrent pituitary tumors must be individualized. Treatment may include re-operation, radiation therapy and/or medical therapy, depending on the tumor type and specific situation.

Updated 1/14/15 BS and KKM

Disclaimer About Medical Information: The information and reference materials contained herein is intended solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient's own physician. All visitors to this and associated sites from the Neurosurgical Service at MGH agree to read and abide by the the complete terms of legal agreement found at the Neurosurgery "disclaimer & legal agreements."

Physicians' Pituitary Information Service - Physicians with questions may contact Dr Biller or Dr Klibanski at 617.726.3965 or 1.888.429.6863 or via e-mail at - :: Research Studies

The Neuroendocrine and Pituitary Tumor Clinical Center
Massachusetts General Hospital
Zero Emerson Place, Suite 112, Boston, Massachusetts 02114
Voice: 617.726.7948 & Fax: 617.726.1241
Copyright © 2015 All Rights Reserved.

Powered by eWebs @ MGH Neurosurgery
Developed By PageServant

Privacy Note:This web site uses Google Analytics.